Business Wire

Blockstream’s Bitcoin Mining Security Token Projected to Outperform Direct Bitcoin Investments

6.9.2024 08:00:00 EEST | Business Wire | Press release

Share

Blockstream, the global leader in Bitcoin infrastructure technology, has launched series 3 of its highly anticipated Blockstream Mining Note 2 (BMN2), responding once again to heightened investor interest in Bitcoin mining opportunities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905372943/en/

(Graphic: Business Wire)

BMN2, an EU-compliant hash rate-backed security token, provides direct exposure to Bitcoin hash rate operated by Blockstream’s state-of-the-art, enterprise-grade mining facilities across North America. BMN2 is designed to replicate the first iteration of the Blockstream Mining Note (BMN1), which launched in 2021 and matured in July this year, delivering a 32% bitcoin return over its 3-year term. Arnab Naskar, Co-founder and Co-CEO of STOKR, a digital asset investment platform, declares it “the highest payout in real world asset (RWA) security token history.”

The Bitcoin industry has matured greatly since the launch of BMN1 in 2021. Bitcoin mining-adjacent investment products, such as hash rate contracts and hosted mining services, have become available to investors and businesses. However, these products and services lack investment conveniences — secondary market liquidity, long-term fixed rates, instant exposure, and market timing protection — freedoms that BMN2 provides.

BMN2—the primary offering of which went live on July 18, 2024 raising just under $7M—follows a similar economic model to BMN1, offering a highly competitive hash price for investors and an investment opportunity that can outpace bitcoin purchases on the spot market. Further, BMN2 includes hash rate safeguards that exceed that of its predecessor, including a reserve of 50% of the stated hash rate (1PH/s per day) to protect against potential miner failures, reduced efficiency, and other non-force majeure issues.

Available to qualified, non-US investors via Luxembourg-based virtual assets service provider, STOKR, BMN2 is offered at a set, discounted hash price of $21.23 for 48 months. Bitcoin hash price refers to the short-term profitability of bitcoin mining and measures the revenue that Bitcoin miners can earn. The BMN2 is prominently priced well below the current spot market hash price to incentivize bitcoin holders, investors, and businesses to directly partake in maintaining the Bitcoin network. Each BMN2 security token entitles holders to the bitcoin produced by 1 PH/s (petahash per second) of Blockstream’s mining hash rate, ensuring a consistent stream of bitcoin rewards directly linked to mining performance. BMN2 provides a well-timed onramp for investors to strategically take part in the market before the next bitcoin halving.

Bitcoin mining operations for BMN2 commenced this week at an equivalent hosting rate less than $.045 kWh (kilowatt-hour), which is substantially lower than the industry average of $.065 for enterprises, and $.075 commonly available for retail customers. The strength, reliability, and performance of Blockstream’s advanced mining fleet allows for the extension of favorable terms to the greater Bitcoin community to contribute to the network’s decentralization. Additionally, over 80% of BMN2 power is derived from carbon neutral sources—wind, solar, and nuclear—making it a conscientious investment opportunity that aligns investor interests, community collaboration, and offers an attractive entry point relative to the historical hash price market.

“Operational excellence and integrity are at the core of our mining business,” said Chris Cook, CIO of Blockstream. “We know first-hand the complexities involved in mining Bitcoin—hardware challenges, energy curtailment, and price fluctuation, to name a few. We created the BMN product to deliver a consistent hash rate with the goal of maintaining a strong and steady investment outcome.”

Blockstream’s leadership in Bitcoin mining is well-established. It traces its roots back to CEO and Co-founder Dr. Adam Back’s invention of the HashCash algorithm behind the proof-of-work protocol, a fundamental component of Bitcoin’s security architecture. Dr. Back’s pioneering work laid the groundwork for Bitcoin, and his ongoing contributions with the BMN and BASIC note, another Blockstream mining offering, to continue to shape the future of the entire real world asset industry.

For access to the BMN2 security token offering and regular updates, eligible investors can register at https://stokr.io/featured-assets/blockstream-mining2.

About Blockstream Mining

Founded in 2014, Blockstream is the global leader in Bitcoin and blockchain infrastructure. Blockstream Mining offers turnkey Bitcoin mining services and solutions designed to provide institutions full transparency and control over their mining operations. By providing secure state-of-the art facilities for a reliable miner colocation, coupled with exceptional technical talent infrastructure, Blockstream Mining purpose-built data centers meet the strict physical and network security requirements of global institutional and enterprise customers. Keeping mining carbon emissions to a minimum, current mining sites are located in the US and Canada, using a majority of non-fossil power sources.

About STOKR

STOKR is at the forefront of transforming financial assets for the digital era. As a leading digital investment platform, STOKR helps asset managers, fund managers, and issuers to tokenize and manage a diverse range of financial assets. STOKR’s platform simplifies the entry into the world of digital securities with a comprehensive suite of services that includes dedicated investment structures, state-of-the-art technology infrastructure, and full-scale support in payments and compliance.

With STOKR, clients can effortlessly issue digital securities and foster strong investor relationships, benefiting from enhanced liquidity thanks to the integration with secondary markets. STOKR’s approach removes the technical complexities typically associated with digital securities, offering a seamless investment experience. Leveraging over six years of innovation and expertise in the digital securities market, STOKR provides a sophisticated and secure environment for capital raising.

Registered as a Virtual Assets Service Provider (VASP) with the CSSF in Luxembourg, STOKR is committed to the highest standards of regulatory compliance, ensuring a reliable and trustworthy platform for all stakeholders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905372943/en/

Contacts

Sarah L. Macedonio
sarah@mining.blockstream.com
(860) 573-9580

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye